Erika B-Cure Laser Ltd.

bcurelaser.com ; bcurelaser.co.il

Formerly Erika Carmel

High-Tech Company
Public Company

(TASE: ERKA)

TECH VERTICALS

Lasers Dental, Healthtech, Life Sciences, Medical Devices, MedTech, Orthopedics, Pain Relief, SportsTech, Veterinary

General Data

Sector	Medical Devices
Company Stage:	Revenue Growth
Established	2007
Number of Employees	60
Employees in Israel	50
Reg. Number:	abCDe

DESCRIPTION

Erika B-Cure Laser is an international company which develops, markets and distributes the B-Cure Laser products. Designed to treat acute and chronic pain, orthopaedic disorders, wounds and inflammations, these revolutionary non-invasive, safe, lightweight and portable pain relief devices are brought to the market for daily domestic use at home.

TECHNOLOGY

B-Cure Laser is based on LLLT (Low Level Laser Therapy) technology, that may treats the pain and its source effectively. B-Cure Laser’s efficacy and safety was proven in several double-blind studies, all of which confirmed its clinical value.

Products and Phases

Product	Phase
B-Cure Laser Classic	FDA Approved CE Approved MDSAP Canada, AMAR
Low Level Laser Treatment (LLLT 808) for professional and personal treatments of: knee pain, pain in neck lower and upper back, sports injuries, muscle pain, arthritis, fibromyalgia, tennis elbow, Achilles tendonitis, carpal tunnel syndrome, inflammation, wound healing, burns, fresh surgical scars, post-pregnancy stretch marks, acne, herpes simplex, dental medicine, acupuncture.
B-Cure Laser Pro	FDA Approved CE Approved MDSAP Canada, AMAR
B-Cure Laser Pro is a more powerful version than the B-Cure Laser Classic. B-Cure Laser Pro is suitable for applications at clinics by professionals as well as for home use and is particularly indicated for the treatment of wounds and ulcers. It can be used as an adjunct treatment for conditions such as carpal tunnel syndrome, fibromyalgia, knee pain, neck pain, lower and upper back pain, wounds, pressure sores, diabetic ulcers and some sports injuries. Suitable for treatment of both acute and chronic problems.

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Clinics, Hospitals, Sports teams, Athletes, Security forces, Home care, Nursing homes, and individuals for self-treatments at home.

	BUSINESS MODEL
	B2B

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Accounting Firm

CONTACT INFO

Expand / Collapse All

Main Address: Haifa, Israel

Address	5 Nachum Heth St., Carmel Hi-Tech Park
City	Haifa
Country	Israel
Zip	3508504

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: London, United Kingdom

City	London
Country	United Kingdom

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: United States

Country	United States

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Canada

Country	Canada

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Ronen Goldstein	CEO	WaterGen (VP, Operations)
Mr. Aviram Cohen	CFO	MIND CTI (CFO)
Mr. Itay Avni	VP, Business Development & Global Sales
Mr. Guy Ben-Simon	Sales Department Manager, Israel
Mr. Eli Shoten	Director of Operations
Ms. Ilanit Kopler-Klein	HR Manager
Mr. Michael Schlosser	Co-Founder
Ms. Zipora Schlosser	Co-Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Former Chairman, Shufersal & Director at IEC - Israel Electric Corporation
abC Defghij	Board Member	Co-Founder, Erika B-Cure Laser Ltd.
abC Defghij	Board Member	Co-Founder, Erika B-Cure Laser Ltd.
abC Defghij	Board Member	CEO, Agrekal
abC Defghij	Board Member	Business & Financial Counselor

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Jul. 27, 2021	IPO	TASE	abCDe	abCDe	Raised a total of NIS 108m; $27m (NIS 87.5m) from shares sold by the company and $6m (NIS 20.5m) from shares sold by shareholders; Valuation = NIS 430m.

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Mar. 24, 2026

Revenue Growth

abCDe

NIS 2.5m

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Private Investor	abCDe	NIS 1.25m. Holds 4.8%.
abC Defghij	Private Investor	abCDe	NIS 1.25m. Holds 4.8%.

Last Updated:	abCDe
IVC Number:	abCDe